The Rocket Innovation Award recognises advances in sustained therapeutic protein delivery to the CNS, including the Myo-P5A® programme in development for Sanfilippo syndrome type IIIA Campus Innovation Park, Geneva, Switzerland, 23 October 2026 / EIN Presswire : Release Therapeutics (“Release Tx” or “the Company”), a privately held Swiss BioMedTech company, today announced that a collaborative research project involving Release Tx, Geneva University Hospitals (HUG) and the Un

The competitive, non-dilutive funding reflects confidence in the scientific and translational potential of the Company’s encapsulated cell technology platform and supports its expansion into a second rare CNS indication. Campus Innovation Park, Geneva, Switzerland, 22 October 2026 / EIN Presswire : Release Therapeutics (“Release Tx” or “the Company”), a privately held Swiss BioMedTech company, today announced that it has been awarded a CHF 500,000 Innovation Project grant fro

Peer-reviewed preclinical study in a colorectal cancer model demonstrates antitumour activity and immune modulation within the tumour despite substantially lower systemic antibody exposure than systemic ipilimumab, with lower systemic exposure associated with fewer observable signs of treatment-related toxicity. Release Therapeutics (Release Tx) is pleased to announce the publication of a new peer-reviewed preclinical study in iScience, a Cell Press journal, evaluating the us

When gene therapy for metachromatic leukodystrophy (MLD) was approved in Europe in 2020, followed by approval in the United States in 2024, it offered affected families something they had never had access to before: a disease-modifying treatment for this devastating form of childhood dementia. For the first time, it showed that the course of MLD could be meaningfully altered when treatment is delivered early enough. In real-world practice, however, early intervention remain

The award recognises a personalised cancer immunotherapy vaccine developed by UNIGE and HUG that originated at MaxiVax (now Release Therapeutics) Release Therapeutics (Release Tx) is pleased to announce that our research collaborators at the University of Geneva (UNIGE) and Geneva University Hospitals (HUG) have been awarded the 2026 Pfizer Research Prize in Oncology for their work on the personalised cancer vaccine MVX-ONCO-1. [i] Established in 1992, the Pfizer Research Pr

The white matter of the brain was once disregarded by scientists as passive tissue and secondary to grey matter, where neurons reside....

We are pleased to share that Release Therapeutics has been selected as one of 10 Swiss startups to participate in the 5th Innovation...

The agreement unlocks new potential for the clinical development of the legacy oncology platform, as Release Therapeutics advances its...

We are proud to announce that our latest data on our Encapsulated Cell Therapy for Metachromatic Leukodystrophy (MLD) will be showcased...

We are thrilled to announce that Release Therapeutics has been selected to present at the Emerging Biotech Company Track at Swiss Biotech...

Rare Disease Day isn’t about numbers. It’s about people—the individual and their family whose world is forever shifted by a diagnosis...

The field of lysosomal disorders is making great strides, with breakthroughs in basic science paving the way for potential new...

We are thrilled to announce that Release Therapeutics is attending the 21st annual WORLDSymposium ™ on Lysosomal Disease Research held...

Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...

We are thrilled to introduce Release Tx's Scientific Advisory Board (SAB), which brings together leading experts in leukodystrophies,...

All of us at Release Tx are excited to be participating in the the 134th SICTIC Investor Day at IMD, Lausanne on 28 November 2024, where...

We’re pleased to announce that Release Therapeutics will be attending Founders’ Evening, organised by Lenz & Staehelin on 20 November at...

We are pleased to announce that Release Tx will participate in the upcoming Cell Press LabLinks Tumor Immunology and Immunotherapy...

Release Therapeutics is pleased to announce our participation in the European Society of Gene and Cell Therapy (ESGCT) Congress that will...

Release Therapeutics is thrilled to announce our participation in FutureHealth Lausanne 2024, which kicks off at the SwissTech Convention...